SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (607)10/29/2021 8:03:11 PM
From: JamesK1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (1) | Respond to of 684
 
They report quarterly results next week. This is what they said last quarter...

  • Expect to deliver three key clinical milestones in second half of 2021:
  • Dose first patients in global Phase 1/2 trials for PBFT02 and PBKR03 in 3Q21
  • Report initial safety and 30-day biomarker data from Imagine-1 global Phase 1/2 trial of PBGM01 for the treatment of infantile GM1 in 4Q21





  • To: scaram(o)uche who wrote (607)10/30/2021 10:49:22 AM
    From: bmaz0011 Recommendation

    Recommended By
    scaram(o)uche

      Respond to of 684
     
    $PASG. GM1 gangliosidosis. First patient dosed 4/1/2021. Phase 1/2 initial biomarker and safety data due 4Q 2021.

    NCT04713475